4 views left Get unlimited views with a free account

Take your business to the next level. Explore the latest trends and actionable insights to inform business strategy and pinpoint opportunities and risks.

Number of ongoing Clinical Trials (for drugs) involving Inguinal Hernia by Phase

Industry: Pharmaceuticals
Current: Other Industry Indicators

There are currently 55 ongoing clinical trials involving Inguinal Hernia
Of the 55 trials,32 trials are in Phase II
Furthermore, 6 trials are in Phase III

Number of ongoing Clinical Trials (for drugs) involving Inguinal Hernia by Phase

View as table

The global pharmaceutical industry is steadily developing new drugs for Inguinal Hernia, a gastrointestinal indication. Asia-pacific boasts of the highest number of ongoing clinical trials involving Inguinal Hernia. Europe and North America are among some of the other prominent regions involved in Inguinal Hernia-related drug trials.

Inguinal Hernia related clinical trial sponsors

Innocoll Holdings Ltd, Heron Therapeutics Inc, Kantonsspital Baden AG, King Edward Memorial Hospital, King Edward Memorial Hospital, Ataturk University, S.Nijalingappa Medical College & H.S.K. Hospital & Research Center, Ain Shams University, University of Southern Santa Catarina, and University of Tsukuba are some notable sponsors involving Inguinal Hernia. A clinical trial sponsor can be a Company, Government, Individual, or Institution.

Marketed Drugs involving Inguinal Hernia

Ofloxacin + ornidazole(Ofspan-Oz), anddiflucortolone + isoconazole(Isoconazole Nitrate + Diflucortolone Valerate)are the key marketeddrugs involving Inguinal Hernia.     

Ofloxacin and Ornidazole (Ofspan-Oz) is a fixed dose combination drugs in which ofloxacin is a fluorinated carboxyquinolone and ornidazole is a 5-nitroimidazole derivative. Ofloxacin and Ornidazole functions via the following Mechanism of Action: DNA Gyrase (EC 5.99.1.3) Inhibitor, DNA Synthesis Inhibitor, and DNA Topoisomerase IV (EC 5.99.1.3) Inhibitor.

ofloxacin + ornidazole (Ofspan-Oz) is used for the treatment of Inguinal Hernia and several other indications including Amoebic Dysentery, Otitis Externa, Otitis Media, Acute Epiglottitis, Acute Tonsillitis, Complicated Intra-Abdominal Infections, Dental Abscess, Infectious Diarrhea, Mastoiditis, Pelvic Inflammatory Disease (Pelvic Infections), Periodontitis, Rhinosinusitis, Skin and Soft Tissue Infections, and Surgical Wound Infections.Ofspan-Oz is sold in India by Pharmatech Healthcare. It is formulated as tablet for oral route of administration and injectable solution for intravenous route of administration.

Diflucortolone valerate and isoconazole nitrate (Isoconazole Nitrate + Diflucor) is a fixed dose combination drug. It is formulated as cream for topical application. Diflucortolone valerate and isoconazole nitrate functions via the following Mechanism of Action: Glucocorticoid Receptor (GR or Nuclear Receptor Subfamily 3 Group C Member 1 or NR3C1) Agonist; Lanosterol 14 Alpha Demethylase (Sterol 14 Alpha Demethylase or Cytochrome P450 14DM or Cytochrome P450LI or Cytochrome P450 51A1 or CYPLI or CYP51A1 or EC 1.14.14.154) Inhibitor.

Diflucortolone valerate and isoconazole nitrate is marketed for the treatment of fungal infections of Inguinal Hernia and several other indications including Atopic Dermatitis (Atopic Eczema), Erythrasma, Hand Dermatitis, Tinea Versicolor (Cutaneous Mycoses).Isoconazole Nitrate + Diflucortolone Valerate is sold in China by Bright Future Pharmaceutical Laboratories Ltd.